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Objective
Sepsis is a life-threatening systemic inﬂammatory
response caused by severe infection.1 Investments in
biomedical, clinical and operational research are
poorly documented.2 Recent studies have attempted
to map and evaluate investments in infectious disease
research in the UK and the gender of the principal
investigators.3,4 We aimed to analyse the UK invest-
ments in sepsis research.
Design
A systematic analysis of infectious disease research
funding to UK institutions was conducted. A total
of 6615 infection-related studies by public and phil-
anthropic funding organisations were included in the
full analysis. We included all sepsis-related research
for the period 1997 to 2010 and studies where the lead
institution was in the UK. We excluded open-access
data from the pharmaceutical industry, as it was
under-representative of the total research undertaken
by the industry.
Setting
Research institutions in the UK and their global
partners.
Participants
A total of 6,165 infection-related studies and 79
sepsis-related studies were included in this systematic
analysis.
Main outcome measures
Variables collected included study title, abstract, total
funding for the study, lead institution, funding
organisation, principal investigator and year of
award. Studies were categorised by disease, crosscut-
ting theme and research and development (R&D)
value chain. Funding awarded in currency other
than UK pounds (£) was converted using the mean
exchange rate in the year of award. Funding was
adjusted for inﬂation and reported in 2010 UK
pounds. Studies were categorised and double-checked
by two authors. Fixed marginal kappa score was
0.950, suggesting a high level of agreement.
Results
We identiﬁed a total research investment in sepsis of
£20.6 million across 79 studies, accounting for 0.79%
of total research investment in infectious diseases,
which was £2.6 billion.
Figure 1 shows investment by R&D value chain.
Preclinical research attracted the most investment
with £16.3 million (78.9%) followed by phase 1, 2,
3 clinical trials with £2.0 million (9.7%) and epi-
demiological and operational research with £1.4 mil-
lion (7.0%). Product development research was the
least well-funded type of research by public
and philanthropic funding organisations with £0.9
million (4.4%).
Assessing by gender of the principal investigator,
men were awarded 84.8% of total funding, with
women receiving 15%.
Diagnostic tools for control accounted for £2.0
million (9.5%). Studies assessing therapeutic options
accounted for £6.0 million (29.0%).
Public funding accounted for £10.9 million
(53.1%) across 36 studies with philanthropic funding
awarding £9.3 million (44.9%) across 28. The leading
funding organisations to support this work included
the Medical Research Council with £8.8 million
(43.1%), followed by the Wellcome Trust with £4.6
million (22.2%).
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Conclusions
We present the ﬁrst detailed analysis of funding
awarded for sepsis research to UK institutions and
their global partners.
Sepsis receives a small amount of funding com-
pared with other infectious diseases, despite its sig-
niﬁcant burden of disease. We anticipate this study
to underestimate the total investment in sepsis
research, as ﬁndings from certain studies that
were not explicitly looking at sepsis may still have
an impact more broadly. We urge the pharmaceut-
ical industry to openly publish their investment
data, in order to reduce unnecessary duplication
of research and enhance the allocation of scarce
resources.5
It is essential we map, monitor and evaluate
research funding given the importance of sepsis and
infectious diseases to global health.
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2 Journal of the Royal Society of Medicine Open 5(9)
 at University College London on November 26, 2014shr.sagepub.comDownloaded from 
Contributorship: MGH designed the study. JRF analysed the
data and created the ﬁgure with input from MGH and RA.
JRF interpreted the data and wrote the draft and ﬁnal versions
with input from MGH and RA. All authors reviewed and
approved the ﬁnal version.
Acknowledgements: We thank the Infectious Disease Research
Network for their contribution to this work, and acknowledge the
assistance of the research and development funding agencies for
provision of data. We also thank Fatima Wurie, Mary Cooke and
Andrew Hayward for their input into earlier work analysing
research investments and disease burden.
Provenance: Not commissioned; peer-reviewed by Peter Kemp
References
1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving
sepsis campaign guidelines committee including the
pediatric subgroup. Surviving sepsis campaign: inter-
national guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med 2013; 41:
580–637.
2. Ravishankar N, Gubbins P, Cooley RJ, et al. Financing
of global health: tracking development assistance for
health from 1990 to 2007. Lancet 2009; 373: 2113–2124.
3. Head MG, Fitchett JR, Cooke MK, Wurie FB,
Hayward AC and Atun R. UK investments in global
infectious disease research 1997–2010: a case study.
Lancet Infect Dis 2013; 13: 55–64.
4. Head MG, Fitchett JR, Cooke MK, Wurie FB and Atun
R. Differences in research funding for women scientists:
a systematic comparison of UK investments in global
infectious disease research funding during 1997–2010.
BMJ Open 2013; 3: e003362.
5. Head MG, Fitchett JR and Atun R. Global health prio-
rities and research funding. Lancet Infect Dis 2013; 13:
653.
Fitchett et al. 3
 at University College London on November 26, 2014shr.sagepub.comDownloaded from 
